share hit ms drug suspension share elan biogen idec plunge monday firm suspend sale new multiple sclerosis drug tysabri patient death u new york stock exchange share elan lose u partner biogen idec shed firm take action death central nervous system disease suspect case condition case cite involve use tysabri avonex biogen idec exist multiple sclerosis drug company say report rare condition progressive multifocal leukoencephalopathy pml patient take either tysabri avonex alone tysabri approve use u last november widely tip become world lead multiple sclerosis treatment company work clinical investigator evaluate patient consult lead expert well understand possible risk pml two firm say statement outcome evaluation use determine possible dose clinical trial future commercial availability analyst believe product would provide new growth opportunity biogen idec face increase competition rival avonex elan big firm irish stock exchange also expect receive boost new product inquiry elan account bring group close bankruptcy firm rebuild since share price increase almost last year value company tysabri say ian hunter goodbody stockbroker dublin question mark elan finish biogen fell share uk pharmaceutical firm phytopharm close penny london stock exchange monday say partner set pull deal experimental alzheimer disease treatment phytopharm say japan yamanouchi pharmaceutical likely end licensing agreement prompt analyst raise question level future cash reserve